About

Company

Lineagen helps physicians personalize medical management for individuals with developmental delay and autism spectrum disorder by providing cutting-edge genetic testing services.

We make genetic testing accessible to everyone, from patient to provider, by combining simple non-invasive sampling, and advanced testing technology with dedicated service and support. Whether it's understanding your test results or navigating the insurance process, we help you every step of the way.

In the past, healthcare providers would often advise parents to “wait and see” because they simply didn’t have many tools to diagnose the underlying genetic cause for a child’s developmental delay. Today, FirstStepDx PLUS® CMA testing service helps providers pinpoint the cause of delay and develop a personalized healthcare management program for their patient. Testing today means treating correctly sooner.

Our FirstStepDx PLUS uses chromosomal microarray (CMA) testing technology, which can detect hundreds of genetic conditions and is recommended as the first-tier test for global developmental delay according to nationally accepted guidelines. Moreover, our test has the highest detection rate of any commercially available test.

For parents, one of the most important differences in our test is that we don’t require a blood draw to get a DNA sample. Instead, no needles, no tears; the FirstStepDx PLUS uses a painless cheek swab for DNA sampling.

After your test is run, we give you the results in plain English, in a detailed and personalized report anyone can understand. If you have questions, you can contact our team of genetic counselors.

Finally, we are the insurance reimbursement experts. Our team of reimbursement specialists handles everything, from pre-authorizations to appeals, so the insurance burden doesn’t fall on you or your doctor.

While there are many laboratories that provide genetic testing, Lineagen is the only laboratory that provides these additional levels of service for families.

company-graphic

Year Lineagen was founded

icon-quote

Trust

We will succeed based on establishing and maintaining trust relationships with our customers who are healthcare providers, patients, their families, and those who pay for their healthcare.

icon-quote

Value

We create value for customers, shareholders, employees, and the communities in which we live.

icon-quote

Urgency

We are compelled to deliver our best services as soon as practicable.

icon-quote

Personal

Our services focus on providing hope, compassion, and assistance to the customer as an individual.

icon-quote

Integrity

We will not sacrifice integrity for expediency, and commit to you that our services have a sound scientific basis.

Team

Michael S. Paul, Ph.D.
CEO, President, Co-Founder

Dr. Paul is a co-founder and has served as Chief Executive Officer of Lineagen since its inception. Dr. Paul has been recognized as one of Utah’s leading venture entrepreneurs and was a Utah Governor’s Appointee to the Steering Committee for the Utah Technology Industry Commission. Prior to Lineagen, he was President and Chief Operating Officer of Lineagen Research Corporation, Vice President of Business Development at Huntsman Biotechnology Corporation and Director of Strategic Development at NPS Pharmaceuticals.

Dr. Paul has also worked at the University of Utah Technology Transfer Office where he participated in the marketing of University inventions to the pharmaceutical and biotechnology industries. Dr. Paul is a licensed patent agent of the United States Patent and Trademark Office. Dr. Paul earned his B.A. from Colby College and his Ph.D. in Molecular Biology and Biochemistry from the University of Utah.

Holly Bauzon
Senior Vice President, Commercial Operations

Holly Bauzon is Lineagen’s Senior Vice President of Commercial Operations and joined Lineagen with more than 20 years of healthcare experience. Prior to joining Lineagen, Ms. Bauzon was the Vice President of Managed Markets at Vermillion, Inc. Ms. Bauzon has a proven track record in both increasing sales traction and expanding payer coverage for laboratory services companies. At PerkinElmer she was the Director of Lab Services Sales and Managed Markets, prior to PerkinElmer, she held commercial management and payer relations positions at PolyMedica Corporation, National Diabetic Pharmacies, Inc. and Byram Healthcare, Inc.

Ms. Bauzon has a Bachelor of Science degree in Health Science from East Stroudsburg University.

David Jansen
Vice President, Marketing
David Jansen is Lineagen's Vice President of Marketing. He brings with him more than 25 years of global experience in diagnostics and medical devices. Most recently, Mr. Jansen was Vice President of Marketing at Vermillion, Inc. He has held positions in marketing and sales leadership at Myriad Genetics, Bacchus Vascular, Bard Access Systems (a division of C.R. Bard), and the Medical Products Division of W.L. Gore & Assoc., Inc.


Mr. Jansen holds an undergraduate degree in Biology and Chemistry from Northern Arizona University and an MBA in Global Management from the University of Phoenix.

Rena Vanzo, M.S., L.C.G.C.
Vice President, Clinical Genetics
Rena Vanzo heads Lineagen's Genetic Counseling Team within the Clinical Services Team. She provides physicians and families with consultation, education, and support throughout the testing and evaluation process.
 

Ms. Vanzo was formerly a clinical pediatric and metabolic genetic counselor at the University of Utah's Department of Pediatrics. She received her Master of Science in Medical Genetics from Indiana University (2008) and her Bachelor of Science in Psychology from the University of Wisconsin (2004).

E. Robert Wassman, M.D.
Chief Medical Adviser

E. Robert Wassman, M.D. is Lineagen’s Chief Medical Adviser and joined Lineagen with more than 30 years of experience in genetics-based diagnostics. Prior to joining Lineagen, Dr. Wassman served in various positions focused on advancing the translation and delivery of cutting-edge diagnostic technology into clinical service, including Chief Medical Officer at Rosetta Genomics; Chief Medical and Chief Genomics Officer at Generation Health; SVP/CMO of Helicos BioSciences; Co-Founder and CMO of Good Start Genetics, and President/CMO of Celula, Inc. Prior to leading these start-up ventures, he was the Senior Medical Officer of Genzyme Genetics after helping lead Alfigen/The Genetics Institute for many years. In addition he has served as a consultant to numerous companies introducing other key innovations to the market.

Dr. Wassman received his B.S. from Yale University, and his M.D. from Albany Medical College. He took post-graduate training in Pediatrics and Medical Genetics at NY Hospital-Cornell University Medical Center and UCLA respectively, and is Board certified in these disciplines.
Francis Ota
Chief Financial Officer
Francis Ota is Lineagen's Chief Financial Officer (CFO). He has served as a Senior Finance Executive with a number of leading healthcare companies in the U.S.  Most recently, Mr. Ota was Executive Vice President of Finance at MDxHealth. Prior to that, he was the Chief Financial Officer of Captek Holdings, a specialty pharmaceutical company, and Senior Director of Finance at Focus Diagnostics, Inc. a CLIA service laboratory acquired by Quest Diagnostics in 2006. Mr. Ota also held senior finance roles with Medtronic and Hewlett Packard.
  

Mr. Ota earned a Master in Business Administration (MBA) from the Haas School of Business, University of California, Berkeley, and a Bachelor of Science in Finance and International Business from Leeds School of Business, University of Colorado, Boulder.

Andy Peiffer, M.D., Ph.D.
Director, Pediatric Genetics

Dr. Peiffer is a co-founder and heads Lineagen's pediatric genetics efforts within Lineagen's Clinical Services Team, overseeing the company's expanding science portfolio and clinical intelligence work. A practicing physician with a current appointment in Pediatric Genetics at the University of Utah, as well as former investigator in the Department of Human Genetics at the University of Utah, Dr. Peiffer combines expertise in both the medical and scientific significance of clinical genetics.

Dr. Peiffer earned his Bachelor's degree in Physiology from McGill University, and his graduate/postgraduate degrees in Medicine, Pharmacology and Physiology from Laval University.

Genetic Counseling Team
Genetic Counselors and Genetic Counselor Assistants
Rena Vanzo, M.S., L.C.G.C.
Vice President, Clinical Genetics
Rena Vanzo heads Lineagen's Genetic Counseling Team within the Clinical Services Team. She provides physicians and families with consultation, education, and support throughout the testing and evaluation process.
 

Ms. Vanzo was formerly a clinical pediatric and metabolic genetic counselor at the University of Utah's Department of Pediatrics. She received her Master of Science in Medical Genetics from Indiana University (2008) and her Bachelor of Science in Psychology from the University of Wisconsin (2004).

E. Robert Wassman, M.D.
Chief Medical Adviser

E. Robert Wassman, M.D. is Lineagen’s Chief Medical Adviser and joined Lineagen with more than 30 years of experience in genetics-based diagnostics. Prior to joining Lineagen, Dr. Wassman served in various positions focused on advancing the translation and delivery of cutting-edge diagnostic technology into clinical service, including Chief Medical Officer at Rosetta Genomics; Chief Medical and Chief Genomics Officer at Generation Health; SVP/CMO of Helicos BioSciences; Co-Founder and CMO of Good Start Genetics, and President/CMO of Celula, Inc. Prior to leading these start-up ventures, he was the Senior Medical Officer of Genzyme Genetics after helping lead Alfigen/The Genetics Institute for many years. In addition he has served as a consultant to numerous companies introducing other key innovations to the market.

Dr. Wassman received his B.S. from Yale University, and his M.D. from Albany Medical College. He took post-graduate training in Pediatrics and Medical Genetics at NY Hospital-Cornell University Medical Center and UCLA respectively, and is Board certified in these disciplines.
Michael S. Paul, Ph.D.
CEO, President, Co-Founder

Dr. Paul is a co-founder and has served as Chief Executive Officer of Lineagen since its inception. Dr. Paul has been recognized as one of Utah’s leading venture entrepreneurs and was a Utah Governor’s Appointee to the Steering Committee for the Utah Technology Industry Commission. Prior to Lineagen, he was President and Chief Operating Officer of Lineagen Research Corporation, Vice President of Business Development at Huntsman Biotechnology Corporation and Director of Strategic Development at NPS Pharmaceuticals.

Dr. Paul has also worked at the University of Utah Technology Transfer Office where he participated in the marketing of University inventions to the pharmaceutical and biotechnology industries. Dr. Paul is a licensed patent agent of the United States Patent and Trademark Office. Dr. Paul earned his B.A. from Colby College and his Ph.D. in Molecular Biology and Biochemistry from the University of Utah.

David Kabakoff
Chairman

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007, and also serves as a partner in HealthQuest Capital. Dr. Kabakoff has more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. He served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by Astra Zeneca), as a Director of InterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).  He currently serves as the Chairman of the Board of Lineagen and as an Observer to the Board of Castle BioSciences and of Histogenics.

Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drugs, and served as Chairman and Chief Executive Officer (acquired by Cephalon Inc.).  Dr. Kabakoff also held the positions of Executive Vice President of Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development Corp. Prior to Dura, Dr. Kabakoff was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

Dr. Kabakoff received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.

Stephen M. Prescott, M.D.
Independent Director, Co-founder

A founding member of Lineagen Research Corporation as well as Lineagen, Inc., Dr. Prescott was previously the Executive Director of the Huntsman Cancer Institute, where he held the prestigious H.A. & Edna Benning Presidential Endowed Chair.

Dr. Prescott was appointed by former Secretary of Health and Human Services, Michael O. Leavitt, to the National Advisory Council for Human Genome Research, which advises the Department of Health and Human Services (DHHS), the National Institutes of Health (NIH), and the National Human Genome Research Institute (NHGRI). 

Dr. Prescott earned a B.S. from Texas A&M and his M.D. from the Baylor College of Medicine.

Fred Middleton
Sanderling Biomedical Ventures

With almost 30 years experience in the biotechnology and biomedical industries, Mr. Middleton currently has active roles as Chairman, CEO, or Director of Sanderling portfolio companies, including Stereotaxis (NASDAQ: STXS), Favrille (NASDAQ: FVRL), CardioNet, Novocell, Cylene, Endocyte and Actimis.

Mr. Middleton was a co-founder of Genentech, where he served as VP of Finance, Administration, Corporate Development, and CFO. He also served as President of Genentech Development Corporation. During his time at Genentech, he concluded more than $200 million in partnering and institutional funding, including Genentech's IPO, a first-ever in the biotechnology industry. Mr. Middleton founded Morgan Stanley Ventures in 1984.

Mr. Middleton earned a B.S. in chemistry from MIT and an MBA with distinction from Harvard Business School.

Ron Heinz
Signal Peak Ventures

Building upon an extensive career in the information technology sector, Mr. Heinz is a founding partner and managing director of Signal Peak Ventures.  Mr. Heinz guides operations for the venture capital and growth equity firm, with over $500 million of assets under management.  As a former operating executive, he spends significant time with portfolio companies helping incorporate their technology into viable business structures.

Prior to Signal Peak, Mr. Heinz was a managing director at Canopy Ventures and previously served as the CEO of Phobos Corporation (acquired by SonicWALL) and Helius Corporation (acquired by Hughes Network Systems), as well as a Senior Vice President at Novell, Inc., where he spent 12 years. 

He holds a B.S. from the Virginia Polytechnic Institute, an MBA from American University and a Masters Certificate in Public Policy from Harvard's Kennedy School of Government.

 

Mary C. Tanner
Independent Director

Mary Tanner is Senior Managing Director of EVOLUTION Life Sciences Partners (ELSP). She is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm.  At Life Sciences Partners, Ms. Tanner specializes in healthcare investment and strategic advisory work.  Before joining ELSP, Ms. Tanner was Senior Managing Director of both Burrill & Company and Burrill Securities. She is a former Senior Managing Director at Lehman Brothers, Bear Stearns and Peter. J. Solomon Company. 

At Lehman Brothers, with Frederick Frank, she headed a global healthcare investment banking franchise for over twenty years. Ms. Tanner has devoted more than 25 years to the global healthcare and biotechnology industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicines, as well as green technologies in chemicals.

In addition to her well-known work with large companies, she specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments and cross-border mergers. Ms. Tanner has directed over 500 mergers and acquisitions, over 130 initial public offerings and hundreds of financings. Ms. Tanner's clients have included Pfizer in its $60 billion acquisition of Pharmacia, Amgen in its $16 billion acquisition of Immunex, Rhône-Poulenc in its acquisition of Rorer, followed by representing Rhône-Poulenc Rorer in its acquisition of U.K. company Fisons, and BASF/BASF Pharma, in its acquisition of U.K. Boots Pharmaceuticals.

Ms. Tanner received a B.A. magna cum laude from Harvard University. Ms. Tanner is a member of the Board of Directors of Lineagen, Inc., a molecular diagnostic company, and Genticel , S.A., an immuno oncology company.  She serves on the Dean's Council of the Yale Medical School and the Yale School of Organization and Management Advisory Board. Ms. Tanner has been honored for her contributions to biotechnology with numerous awards, including the highest award of Springboard Enterprises, the Oracle, for professional accomplishment and mentoring of women entrepreneurs.

Michael J. Walsh
Independent Director

Mr. Walsh has served as a Director since June, 2014.  Mr. Walsh was most recently Executive Vice President, Chief Commercial Officer at Cypress Bioscience, Inc.  In this capacity, Mr. Walsh led the creation of a 115-person sales force and established commercial operations to support the launch of Savella (milnacipran), a pharmaceutical product for fibromyalgia, through a partnership with Forest Laboratories, Inc. as well as personalized medicine services focused in rheumatology.

Prior to Cypress, Mr. Walsh was the founder, Chairman and CEO of Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, which was acquired by Cypress in 2008. Prior to Proprius, Mr. Walsh was co-founder and Executive Chairman at Prometheus Laboratories, where he also held the positions of President, Chief Operating Officer and Chief Executive Officer, from the founding of the company through late 2004. He is largely responsible for developing the company's unique strategy and business model, as well as leading its development into a profitable, integrated specialty pharmaceutical and clinical diagnostics company focused in gastroenterology. 

Prior to Prometheus, Mr. Walsh was with Quidel Corporation in a number of senior executive roles, including Director of Worldwide Marketing and Business Development, and Director of European Operations.  Prior to Quidel, he was Manager of Therapeutic Operations for La Jolla Pharmaceutical Company. 

Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.

David Fitzgerald
Petra Capital

David Fitzgerald has broad experience in both private equity and mergers and acquisitions. Mr. Fitzgerald's primary focus has been on the healthcare, information technology and business services sectors. Prior to joining Petra, Mr. Fitzgerald was a General Partner at Richland Ventures, a venture capital fund with $340 million in assets under management. Earlier in his career, Mr. Fitzgerald led market development and acquisition activities for InformDx, a diagnostic laboratory company and THG Management Services, a managed healthcare company.

Mr. Fitzgerald has board-level experience with many successful growth companies including: SpecialtyCare (sold to American Securities), US Healthworks (sold to Dignity Health), Televox (sold to West Corp.), Appriss (sold to Bain Capital), Synhrgy (sold to Mercer), Nuvox Communications (sold to Windstream), Salveo Specialty Pharmacy (sold to Catamaran). He currently serves as a director on the boards of Urgent Team, New Century Hospice, Opportune IT Healthcare Solutions, Access Media 3, SUN Behavioral Health, Clinipace Worldwide, VirMedica and Lineagen.

Mr. Fitzgerald received a B.A. degree from Washington & Lee University.

Sanderling Ventures
Signal Peak Ventures
Prairiegold Venture Partners
Mesa Verde
Silicon Valley Bank
HealthQuest Capital
Petra Capital Partners
Mountain Group Partners

For more information about investing in Lineagen, please contact Investor Relations at ir@lineagen.com or call us 801.931.6212.

Press Releases

October 19, 2016

Lineagen Announces Launch of Proprietary Variant Index to Improve Interpretation of Genetic Basis for Childhood Developmental Delay

Lineagen, Inc. announced today the presentation at annual meeting of the American Society of Human Genetics (ASHG) and commercial launch of a Proprietary Variant Index
 

Learn more
January 12, 2016

Lineagen Announces Identification of New Genetic Region Associated with Seizures in Wolf-Hirschhorn Syndrome

Lineagen, Inc. announced today the publication of a major study revealing a significant genetic contributor to epilepsy in Wolf Hirschhorn syndrome.

Learn more
View all

Careers

Lineagen is a fast-growing, Salt Lake City-based company that makes diagnostic tests to help healthcare providers and parents provide the most effective treatment for children with developmental delay. We make genetic testing accessible to everyone by combining advanced testing technology with a dedicated team of genetic counselors and reimbursement specialists. Whether it’s understanding test results or handling the insurance process, we help parents and providers every step of the way.

We are currently expanding in many areas of our business and looking for talented individuals who are passionate about helping people and developing new technology to solve our healthcare challenges.

View listing

Contact

Lineagen Inc.

2677 E Parleys Way Salt Lake City, Utah 84109-1617, USA
Telephone: USA [1] 801-931-6200
Fax: USA [1] 801-931-6201
How can we help you?
How did you hear about us?